Use of L-ornithine L-aspartate (LOLA) reduces length of hospital stay in patients with hepatic encephalopathy;Disminución de la estancia hospitalaria con el uso de L-ornitina L-aspartato (LOLA) en pacientes con encefalopatía hepática

Revista de Gastroenterologia de Mexico

Volumn 75, Issue 2, 2010, Pages 135-141

  Abdo Francis, J M ^a   Perez Hernandez J L ^a   Hinojosa Ruiz, A ^a   Hernandez Vasquez J R ^b  

^a O D SSA   (Mexico)

^b Laboratorio de Oncología Genómica   (Mexico)

Author keywords

Cirrhosis; Hepatic encephalopathy; L ornithine Laspartate; Lactulose; Mexico.; Treatment

Indexed keywords

DIPEPTIDE; GASTROINTESTINAL AGENT; LACTULOSE; ORNITHYLASPARTATE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS;

ADULT; AGED; DIPEPTIDES; FEMALE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84858740770     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sistema Nacional de información en Salud [página en internet]. México: SINAIS; c2008 [actualizada 3 de noviembre del 2008]. Mortalidad información tabular. Disponible en: http://sinais.salud.gob. mx/mortalidad.
2. Blei AT, Córdoba J. Hepatic encephalophaty. Am J Gastroenterol 2001;96:1968-1975.
3. Riordan S, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-479. (Pubitemid 27333050)
4. Olosmaa M, Guidotti A, Costo E. Endogenous Benzodiazepines in hepatic encephalopathy. Lancet 1989;1:491-492. (Pubitemid 19063545)
5. Gerber T, Schomerus L. Hepatic encephalopathy in liver cirrhosis. Drugs 2000;60:1252-1370.
6. Butterworth RF. Complications of cirrhosis. Hepatic encephalopathy. J Hepatol 2000;32 (suppl 1):171-180.
7. Uribe M, Guevara L. Encefalopatía hepática. En: Berenguer J, editor. Gastroenterología y Hepatología. 3ra. edición. Barcelona: Editorial Doyma; 2002: 789-803.
8. Hawkes, GA, Thomas O. Hepatic hyperammonaemia: an important, potentially reversible causa of encephalopathy. Postgrad Med J 2001; 77: 717-722.
9. Jenkis DJA, Jenkis A. Wolever TMS, et al. Fiber and starchy foods. Gut function and implications in disease. Am J Gastroenterol 1986;81:920-930. (Pubitemid 16029591)
10. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a fourfold crossover design. J Hepatol 1993;19 424-430. (Pubitemid 24029921)
11. Salvatore F, Cimino F, Ayello Caracciolo M, et al. Mechanism of the protection by L-ornithine-L-aspartate mixture and by L-arginine in ammonia intoxication. Arch Biochem Bio-phys 1964;107:499-503.
12. Vogels BA, Karlsen OT, Mass MA, et al. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats. J Hepatol 1997;26:174-182. (Pubitemid 27072619)
13. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. 1-ornithine- L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999;30:636-40. (Pubitemid 29409406)
14. Kircheis G, Nilius R, Berndt H, et al. Therapeutic efficacy of 1-ornithine- L-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: a placebo-controlled double-blind study. Hepatology 1997;25:1351-60. (Pubitemid 27250753)
15. Stauch S, Kircheis G, Adler G et al. 1-ornithine-Laspartate granulate in the treatment of latent and mild chronic hepatic encephalopathy (HE): a placebo- controlled double-blind study. J Hepatol 1998;28:856-64.
16. Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006;5:281-8. (Pubitemid 44904543)